Skip to main content

Table 1 Demographic and clinicopathologic characteristics of 308 subjects comprising ELISA study cohort and 193 subjects comprising IHC study cohort

From: Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer

 

ELISA Cohort

IHC Cohort

BCa (%) n = 102

Controls (%) n = 206

BCa (%) n = 185

Controls (%) n = 8

Median Age (range, y)

69 (20–93)

56 (18–89)

73 (30–94)

26 (21–43)

Male: Female ratio

84 : 18

152 : 54

143 : 42

4 : 4

Race

    

  White

91 (89%)

135 (66%)

156 (84%)

N/A

  African American

5 (5%)

20 (10%)

8 (4%)

N/A

  Other

6 (6%)

51 (24%)

19 (12%)

N/A

Positive FISH

40 / 74 (54%)

2/22 (9%)

N/A

N/A

Suspicious/positive cytology

37 / 94 (39%)

2/22 (9%)

N/A

N/A

Median follow-up (months)

14

4

18

N/A

Clinical stage

    

  Tis

6 (6%)

 

17 (9%)

 

  Ta

41 (40%)

 

45 (24%)

 

  T1

14 (14%)

 

63 (34%)

 

  ≥T2

41 (40%)

 

60 (33%)

 

Tumor grade

    

  Low

38 (37%)

 

27 (15%)

 

  High

64 (63%)

 

158 (85%)

 

Median tumor size (cm)

3.0

 

3.0

 
  1. IHC immunohistochemistry, BCa bladder cancer, N/A not available.